Internal Server Error

Revolution Medicines - About the company

Revolution Medicines is a public company based in Redwood City (United States), founded in 2014 by Martin Burke, Kevan Shokat and Michael Fischbach. It operates as a Developer of therapies for the treatment of cancer. Revolution Medicines has raised $326M in funding from investors like Third Rock Ventures, Nextech Invest and The Column Group. The company has 3229 active competitors, including 1115 funded and 765 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of therapies for the treatment of cancer. The company's product line include RMC-4630, is a selective inhibitor of SHP2, a central node in the RAS signaling pathway and RMC-5552, is a selective inhibitor of mTORC1, is designed to prevent inactivation of the tumor-suppressive properties of a protein.
Website
revmed.com
Email ID
*****@revmed.com
Phone Number
+1 **********
Registered Address
Redwood City, California
Key Metrics
Founded Year
2014
Location
Redwood City, United States
Stage
Public
Total Funding
$326M in 5 rounds
Latest Funding Round
Ranked
Annual Revenue
$11.6M as on Dec 31, 2023
Employee Count
1,096 as on Apr 30, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Public

Revolution Medicines's IPO details

Revolution Medicines got listed on Feb 13, 2020.
Click here to take a look at Revolution Medicines's IPO in detail
Sign up to download Revolution Medicines' company profile

Revolution Medicines's funding and investors

Revolution Medicines has raised a total funding of $326M over 5 rounds. Its first funding round was on Feb 04, 2015. Its latest funding round was a Series C round on Nov 13, 2019 for $*****. 1 investor participated in its latest round. Revolution Medicines has 14 institutional investors.

Here is the list of recent funding rounds of Revolution Medicines:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Nov 13, 2019
5951142
Series C
3275783
9216960
9610896
9776217
Jul 09, 2019
2110778
Series C
4244317
5989220
5739251
Apr 24, 2018
3437144
Series B
2514178
1019112
lockAccess funding benchmarks and valuations. Sign up today!

Revolution Medicines' founders and board of directors

Founder? Claim Profile
The founders of Revolution Medicines are Martin Burke, Kevan Shokat and Michael Fischbach. Mark Goldsmith D is the CEO of Revolution Medicines.
Here are the details of Revolution Medicines' key team members:

Revolution Medicines' employee count trend

Revolution Medicines has 1,096 employees as of Apr 26. Here is Revolution Medicines's employee count trend over the years:
Employee count trend for Revolution Medicines
lockUncover Revolution Medicines' growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Revolution Medicines's Competitors and alternates

Top competitors of Revolution Medicines include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Revolution Medicines, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Jazz Pharmaceuticals
Jazz Pharmaceuticals
2003, Dublin (Ireland), Public
Developer of novel biopharmaceutical medicines for unmet medical needs
$265M
82/100
2nd
Logo for BeiGene
BeiGene
2010, Cambridge (United States), Public
Developer of targeted and immune-oncology drugs against cancer
$172M
81/100
3rd
Logo for Sana Biotechnology
Sana Biotechnology
2018, Seattle (United States), Public
Developer of engineered cell therapies for treating various human diseases
$821M
75/100
4th
Logo for Senti Biosciences
Senti Biosciences
2016, San Francisco (United States), Public
Developer of cell-based therapies for cancer treatment
$158M
72/100
5th
Logo for Blueprint Medicines
Blueprint Medicines
2008, Cambridge (United States), Acquired
Developer of selective kinase inhibitors for patients with genomically defined cancers
$115M
72/100
6th
Logo for Ideaya Biosciences
Ideaya Biosciences
2015, San Francisco (United States), Public
Developer of oncology-focused precision medicine using molecular diagnostics
$157M
72/100
7th
Logo for Kronos Bio
Kronos Bio
2017, San Mateo (United States), Acquired
Developer of small molecule based therapeutics for cancer treatment
$271M
72/100
8th
Developer of antibody-based therapeutics for cancer therapy
$175M
72/100
9th
Logo for Syndax
Syndax
2005, Waltham (United States), Public
Developer of targeted therapies for the treatment of cancer
$198M
72/100
10th
Logo for Moderna
Moderna
2010, Cambridge (United States), Public
Developer of mRNA-based therapeutics for a wide range of diseases
$2.78B
71/100
100th
Logo for Revolution Medicines
Revolution Medicines
2014, Redwood City (United States), Public
Developer of therapies for the treatment of cancer
$326M
63/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Revolution Medicines's competitors? Click here to see the top ones

Revolution Medicines's Investments and acquisitions

Revolution Medicines has acquired 2 companies including EQRx and Warp Drive Bio. Revolution Medicines has not made any investments as of now.

News related to Revolution Medicines

lockFilter this list
Media has covered Revolution Medicines for a total of 55 events in the last 1 year, 38 of them have been about company updates and 4 about partnerships.
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Revolution Medicines

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford